Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
As a translational researcher, Dr David Rizzieri focused on developing new therapies for patients with leukemia or lymphoma. Dr Rizzieri is a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee. He serves as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last 2 national studies for Burkitt's lymphoma, as well as the recent AML intergroup study. Dr Rizzieri led the team's novel approaches for the care of patients using non-myeloablative allogeneic therapy using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. He also led the first in human studies targeting acute myelogenous leukemia by linking diphtheria to a small molecule targeting the IL-3 receptor (now in phase 3). Dr Rizzieri is currently serving on various NIH/NHLBI grant review committees and is a member of ASH, ASCO, AACR, ASBMT, ASCI, and the ASH sub-committee on Government Affairs. He oversees the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in his clinical research efforts, Dr Rizzieri received the NIH ‘Clinical Investigator Team Leadership Award’ in 2010.
Steven L. Spitalnik
Dr Spitalnik is currently the Executive Vice-Chair and has been a Professor in the Department of Pathology & Cell Biology at Columbia University since 2003. Previously, he was a faculty member in the Departments of Pathology & Laboratory Medicine at the University of Pennsylvania (1985–1998) and the University of Rochester (1998–2003).
He received his undergraduate education in mathematics at Princeton University and his M.D. degree from the University of Chicago. His postgraduate work included residency training in anatomic and clinical pathology at the University of Rochester, and research fellowship training in molecular biology and in glycobiology at the University of Rochester and the National Institutes of Health, respectively.
Dr Spitalnik has held multiple committee and leadership positions in various organizations, such as the AABB, the Academy of Clinical Laboratory Physicians and Scientists, the American Society of Hematology, and the Council of Academic Societies.
Dr Spitalnik has published over 190 papers, edited two books, and has reviewed manuscripts for many journals, including serving on the Editorial Boards of Analytical Biochemistry, Transfusion, and Transfusion Medicine Reviews. In addition, he has served as a member and chair of multiple study sections at the National Institutes of Health and reviewed grant proposals for other domestic and international grant funding agencies.
Dr Spitalnik's research initially focused on glycobiology, particularly on the biosynthesis and immunology of glycoproteins and glycolipids, often using human blood group antigens as models (e.g. in the MNSs, ABH, P, and Lewis blood group systems). Over the last 15 years, he has used cell culture, mouse models, and studies in human volunteers and patient populations to investigate the consequences of red blood cell clearance in several settings, including following transfusions of refrigerator storage-damaged red blood cells, during hemolytic transfusion reactions, in G6PD-deficiency, and in malaria. His research is currently supported by grants from the National Institutes of Health.